Who are MK0663, etoricoxib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Celebrex, Cytotec, Motrin/Percocet/Dilaudid for breakthrough, NSAID (Ketorolac/Ibuprofen), Paracetamol + ibuprofen, Nepafenac (Nevanac).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mk0663-etoricoxib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

MK0663, etoricoxib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MK0663, etoricoxib (MK0663, etoricoxib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: COX-2 inhibitor. Area: Rheumatology.

phase 3 COX-2 inhibitor COX-2 Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

MK0663, etoricoxib (MK0663, etoricoxib) — Organon and Co. Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, reducing prostaglandin synthesis and inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MK0663, etoricoxib TARGET	MK0663, etoricoxib	Organon and Co	phase 3	COX-2 inhibitor	COX-2
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Motrin/Percocet/Dilaudid for breakthrough	Motrin/Percocet/Dilaudid for breakthrough	University Hospitals Cleveland Medical Center	marketed	Combination analgesic regimen (NSAID + opioid + potent opioid)	Cyclooxygenase (COX-1/COX-2); mu-opioid receptor
NSAID (Ketorolac/Ibuprofen)	NSAID (Ketorolac/Ibuprofen)	Thomas Jefferson University	marketed	Non-steroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Paracetamol + ibuprofen	Paracetamol + ibuprofen	Ullevaal University Hospital	marketed	Analgesic/antipyretic combination	COX-1, COX-2 (ibuprofen); prostaglandin synthesis pathway (paracetamol)
Nepafenac (Nevanac)	Nepafenac (Nevanac)	Center For Excellence In Eye Care	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-05-27 — Celebrex · 10722456 · Formulation · US
2036-05-27 — Celebrex · 10799517 · Formulation · US
2036-05-27 — Celebrex · 9949990 · Formulation · US
2036-05-27 — Celebrex · 9795620 · Formulation · US
2036-05-27 — Celebrex · 9572819 · Formulation · US
2036-05-27 — Celebrex · 10376527 · Formulation · US

Sponsor landscape (COX-2 inhibitor class)

Organon and Co · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MK0663, etoricoxib — Competitive Intelligence Brief. https://druglandscape.com/ci/mk0663-etoricoxib. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing